SI-BONE (NASDAQ:SIBN) released its earnings results on Sunday. The company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative return on equity of 45.03% and a negative net margin of 61.67%.
Shares of SI-BONE stock traded down $2.84 during trading on Tuesday, reaching $33.12. The company’s stock had a trading volume of 16,411 shares, compared to its average volume of 287,842. The company has a quick ratio of 12.22, a current ratio of 12.65 and a debt-to-equity ratio of 0.39. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -21.00 and a beta of 1.41. SI-BONE has a 1-year low of $14.37 and a 1-year high of $36.78. The company has a 50-day simple moving average of $33.10 and a two-hundred day simple moving average of $28.78.
In related news, CFO Laura Francis sold 18,358 shares of the company’s stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $33.34, for a total value of $612,055.72. Following the transaction, the chief financial officer now directly owns 197,471 shares of the company’s stock, valued at approximately $6,583,683.14. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jeffrey W. Dunn sold 40,000 shares of the firm’s stock in a transaction on Friday, March 5th. The stock was sold at an average price of $28.65, for a total value of $1,146,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,067,472 shares of company stock worth $32,658,438. 15.50% of the stock is owned by company insiders.
A number of analysts have commented on SIBN shares. JMP Securities upped their target price on shares of SI-BONE from $27.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, January 8th. Canaccord Genuity upped their target price on shares of SI-BONE from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of SI-BONE from a “hold” rating to a “sell” rating in a report on Friday, March 12th. Morgan Stanley increased their price target on shares of SI-BONE from $38.00 to $41.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Truist boosted their price objective on SI-BONE from $35.00 to $43.00 in a research note on Tuesday. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $35.71.
SI-BONE Company Profile
SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Featured Story: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.